Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) were up 4.6% during mid-day trading on Monday . The company traded as high as $17.41 and last traded at $17.27. Approximately 244,025 shares traded hands during trading, a decline of 84% from the average daily volume of 1,543,815 shares. The stock had previously closed at $16.52.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 28th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, ARS Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $31.00.
View Our Latest Research Report on SPRY
ARS Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.30, a current ratio of 11.00 and a quick ratio of 10.74. The firm has a fifty day moving average price of $15.13 and a two-hundred day moving average price of $13.35. The stock has a market capitalization of $1.77 billion, a PE ratio of -112.37 and a beta of 0.90.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The company had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. Research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.
Insider Activity at ARS Pharmaceuticals
In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 50,000 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total transaction of $705,000.00. Following the transaction, the chief financial officer directly owned 7,424 shares in the company, valued at $104,678.40. This trade represents a 87.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander A. Fitzpatrick sold 102,969 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total value of $1,451,862.90. Following the transaction, the insider owned 89,613 shares in the company, valued at $1,263,543.30. The trade was a 53.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,043,118 shares of company stock worth $18,024,863 over the last three months. Corporate insiders own 33.50% of the company's stock.
Institutional Trading of ARS Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of SPRY. Bernard Wealth Management Corp. bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $27,000. ANTIPODES PARTNERS Ltd bought a new stake in ARS Pharmaceuticals during the 1st quarter valued at $37,000. PNC Financial Services Group Inc. boosted its position in ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after acquiring an additional 3,905 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $73,000. Finally, BNP Paribas Financial Markets bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at $75,000. Institutional investors own 68.16% of the company's stock.
About ARS Pharmaceuticals
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Read More
Before you consider ARS Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.
While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.